Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Empagliflozin + telmisartan
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Empagliflozin + telmisartan is a fixed-dose combination of two small molecule drugs used primarily for the management of type 2 diabetes mellitus and hypertension. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary glucose excretion and also provides cardiovascular and renal protective effects. Telmisartan is an angiotensin II receptor blocker (ARB) that reduces blood pressure by selectively blocking the angiotensin II type 1 receptor, leading to vasodilation and decreased aldosterone-mediated volume expansion. The combination targets both glycemic control and blood pressure reduction, addressing comorbidities common in patients with type 2 diabetes[3][4][5][8]. This dual therapy may also reduce the risk of cardiovascular events in high-risk populations.
- Brand names
- Egito
- Other names
- empagliflozin + telmisartan
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)SGLT2 (Sodium-glucose cotransporter protein subunit 2)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on Empagliflozin + telmisartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Empagliflozin + telmisartan.